drugset / Trial / NCT03859323
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of the study is to assess the safety and tolerability of single and multiple ascending subcutaneous (SC) doses of SHP681 in healthy adult participants.
Timeline
- Start
- 2019-03-26
- Primary completion
- 2020-01-06
- Completion
- 2020-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHP681 | Protein / enzyme biologic | 0.2 mg/kg | Subcutaneous |
| Subject | SHP681 | Protein / enzyme biologic | 0.5 mg/kg | Subcutaneous |
| Subject | SHP681 | Protein / enzyme biologic | 1 mg/kg | Subcutaneous |
| Subject | SHP681 | Protein / enzyme biologic | 2 mg/kg | Subcutaneous |
| Subject | SHP681 | Protein / enzyme biologic | 4 mg/kg | Subcutaneous |
Indications
No indication recorded.